October 24, 2022
University of Cincinnati researchers presented results from the first-in-human trial of FLASH radiotherapy at the ASTRO 2022 annual meeting, with data suggesting FLASH may hold promise as a potential treatment for tough-to-kill tumors.
December 8, 2022
Physics World recognized the University of Cincinnati's first-in-human trial of FLASH radiotherapy as one of the Top 10 Breakthroughs of the Year for 2022.
September 16, 2022
WLWT and Yahoo News highlighted work being done by University of Cincinnati Cancer Center researchers to advance cancer care through new immunotherapy and cellular therapy treatments.
October 31, 2018
A new study co-authored by a University of Cincinnati (UC) resident physician and published in the Oct. 31 online edition of the New England Journal of Medicine shows that a non-invasive radical hysterectomy may lead to shorter survival rates than open surgery in women with early-stage cervical cancer.
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
April 26, 2023
WFMZ-TV in Allentown, Pennsylvania highlighted the University of Cincinnati's John Byrd and the Beat AML study testing personalized treatment for patients with acute myelogenous leukemia.
December 8, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Hematology Annual Meeting, held Dec. 9-12 in San Diego, California.
February 15, 2024
The University of Cincinnati Cancer Center announced it is opening the Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, this summer.
February 29, 2024
Regional media highlighted the University of Cincinnati Cancer Center being the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.